Lys108
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys108  -  MEK2 (human)

Site Information
kLIHLEIkPAIRNQI   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 35480414

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
adrenal cancer ( 1 ) , pheochromocytoma ( 1 ) , bladder cancer ( 1 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:

References 

1

Kubota Y, O'Grady P, Saito H, Takekawa M (2011) Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 13, 282-91
21336309   Curated Info